173 related articles for article (PubMed ID: 16525662)
1. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C
Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467
[TBL] [Abstract][Full Text] [Related]
3. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
4. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
[TBL] [Abstract][Full Text] [Related]
5. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
[TBL] [Abstract][Full Text] [Related]
7. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
8. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.
Tamaki K; Sasano H; Ishida T; Miyashita M; Takeda M; Amari M; Tamaki N; Ohuchi N
Cancer Sci; 2010 Sep; 101(9):2074-9. PubMed ID: 20557310
[TBL] [Abstract][Full Text] [Related]
9. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
[TBL] [Abstract][Full Text] [Related]
10. [Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer].
Ying JM; Guo L; Liu XY; Qiu T; Lü N
Zhonghua Yi Xue Za Zhi; 2010 Jun; 90(24):1674-7. PubMed ID: 20979875
[TBL] [Abstract][Full Text] [Related]
11. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
[TBL] [Abstract][Full Text] [Related]
12. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
13. HER2 gene amplification in patients with breast cancer with equivocal IHC results.
Meijer SL; Wesseling J; Smit VT; Nederlof PM; Hooijer GK; Ruijter H; Arends JW; Kliffen M; van Gorp JM; Sterk L; van de Vijver MJ
J Clin Pathol; 2011 Dec; 64(12):1069-72. PubMed ID: 21836036
[TBL] [Abstract][Full Text] [Related]
14. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Huang W; Reinholz M; Weidler J; Yolanda L; Paquet A; Whitcomb J; Lingle W; Jenkins RB; Chen B; Larson JS; Tan Y; Sherwood T; Bates M; Perez EA
Am J Clin Pathol; 2010 Aug; 134(2):303-11. PubMed ID: 20660336
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
[TBL] [Abstract][Full Text] [Related]
16. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
[TBL] [Abstract][Full Text] [Related]
17. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China.
Zhang Z; Yuan P; Guo H; Zhao L; Ying J; Wang M; Zhao H; Pan Q; Xu B
Medicine (Baltimore); 2015 Jun; 94(24):e981. PubMed ID: 26091472
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.
Yang YL; Fan Y; Lang RG; Gu F; Ren MJ; Zhang XM; Yin D; Fu L
Breast Cancer Res Treat; 2012 Aug; 134(3):1095-102. PubMed ID: 22476857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
